Daita Kaneda

Dr. Daita Kaneda

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
TKT. Konno
T. Konno
DBD.F. Broderick
D.F. Broderick
NMN. Mezaki
N. Mezaki
AIA. Isami
A. Isami
DKDaita Kaneda
Daita Kaneda
TITakeshi Ikeuchi
Takeshi Ikeuchi
SUMMARY: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia is a rare neurodegenerative disease resulting from mutations in the colony stimulating factor 1 receptor gene. Accurate diagnosis can be difficult because the associated clinical and MR imaging findings are nonspecific. We present 9 cases with intracranial calcifications distributed in 2 brain regions: the frontal white matter adjacent to the anterior horns of the lateral ventricles and the parietal subcortical white matter. Thin-section (1-mm) CT scans are particularly helpful in detection due to the small size of the calcifications. These calcifications had a symmetric “stepping stone appearance” in the frontal pericallosal regions, which was clearly visible on reconstructed sagittal CT images. Intrafamilial variability was seen in 2 of the families, and calcifications were seen at birth in a single individual. These characteristic calcification patterns may assist in making a correct diagnosis and may contribute to understanding of the pathogenesis of leukoencephalopathy.

10 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BCBin Chen
Bin Chen
MHMd. Mahmudul Hasan
Md. Mahmudul Hasan
HZHengsen Zhang
Hengsen Zhang
QZQing Zhai
Qing Zhai
A.S.M. WaliullahA.S.M. Waliullah
A.S.M. Waliullah
MSMitsutoshi Setou
Mitsutoshi Setou
Ubiquitin-like 3 (UBL3) acts as a post-translational modification (PTM) factor and regulates protein sorting into small extracellular vesicles (sEVs). sEVs have been reported as vectors for the pathology propagation of neurodegenerative diseases, such as α-synucleinopathies. Alpha-synuclein (α-syn) has been widely studied for its involvement in α-synucleinopathies. However, it is still unknown whether UBL3 interacts with α-syn, and is influenced by drugs or compounds. In this study, we investigated the interaction between UBL3 and α-syn, and any ensuing possible functional and pathological implications. We found that UBL3 can interact with α-syn by the Gaussia princeps based split luciferase complementation assay in cells and immunoprecipitation, while cysteine residues at its C-terminal, which are considered important as PTM factors for UBL3, were not essential for the interaction. The interaction was upregulated by 1-methyl-4-phenylpyridinium exposure. In drug screen results, the interaction was significantly downregulated by the treatment of osimertinib. These results suggest that UBL3 interacts with α-syn in cells and is significantly downregulated by epidermal growth factor receptor (EGFR) pathway inhibitor osimertinib. Therefore, the UBL3 pathway may be a new therapeutic target for α-synucleinopathies in the future.

4 November 2022 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
KSKeita Sakurai
Keita Sakurai
DKDaita Kaneda
Daita Kaneda
SMSatoru Morimoto
Satoru Morimoto
YUYuto Uchida
Yuto Uchida
SIShohei Inui
Shohei Inui
YHYoshio Hashizume
Yoshio Hashizume

8 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JYJing Yan
Jing Yan
HZHengsen Zhang
Hengsen Zhang
YTYuna Tomochika
Yuna Tomochika
BCBin Chen
Bin Chen
YPYashuang Ping
Yashuang Ping
MSMitsutoshi Setou
Mitsutoshi Setou
Ubiquitin-like 3 (UBL3) is a membrane-anchored protein that plays a crucial role in sorting proteins into small extracellular vesicles. Aggregations of alpha-synuclein (α-syn) are associated with the pathology of neurodegenerative diseases such as Parkinson’s disease. Recently, the interaction between UBL3 and α-syn was discovered, with potential implications in clearing excess α-syn from neurons and its role in disease spread. However, the regulator that can mediate the interaction between UBL3 and α-syn remains unclear. In this study, using the split gaussian luciferase complementation assay and RNA interference technology, we identified that QSOX2, HTATIP2, UBE3C, MGST3, NSF, HECTD1, SAE1, and ATG3 were involved in downregulating the interaction between UBL3 and α-syn. Notably, silencing MGST3 had the most significant impact. Immunocytochemistry staining confirmed the impact of MGST3 silencing on the co-localization of UBL3 and α-syn in cells. MGST3 is a part of the antioxidant system, and silencing MGST3 is believed to contribute to oxidative stress. We induced oxidative stress with hydrogen peroxide, observing its effect on the UBL3-α-syn interaction, and showing that 800 µM of H2O2 downregulated this interaction. In conclusion, silencing MGST3 downregulates the interaction between UBL3 and α-syn.

12 November 2024 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
KSKeita Sakurai
Keita Sakurai
DKDaita Kaneda
Daita Kaneda
SMSatoru Morimoto
Satoru Morimoto
YUYuto Uchida
Yuto Uchida
SIShohei Inui
Shohei Inui
YHYoshio Hashizume
Yoshio Hashizume

22 October 2024 in Neurology International
Verified
Journal Article
Open access
PDF file
SOSoho Oyama
Soho Oyama
HZHengsen Zhang
Hengsen Zhang
RFRafia Ferdous
Rafia Ferdous
YTYuna Tomochika
Yuna Tomochika
BCBin Chen
Bin Chen
MSMitsutoshi Setou
Mitsutoshi Setou
Background/Objectives: UBL3 (Ubiquitin-like 3) is a protein that plays a crucial role in post-translational modifications, particularly in regulating protein transport within small extracellular vesicles. While previous research has predominantly focused on its interactions with α-synuclein, this study investigates UBL3’s role in Huntington’s disease (HD). HD is characterized by movement disorders and cognitive impairments, with its pathogenesis linked to toxic, polyglutamine (polyQ)-expanded mutant huntingtin fragments (mHTT). However, the mechanisms underlying the interaction between UBL3 and mHTT remain poorly understood. Methods: To elucidate this relationship, we performed hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) on postmortem brain tissue from HD patients. Gaussia princeps-based split-luciferase complementation assay and co-immunoprecipitation were employed to confirm the interaction between UBL3 and mHTT. Additionally, we conducted a HiBiT lytic detection assay to assess the influence of UBL3 on the intracellular sorting of mHTT. Finally, immunocytochemical staining was utilized to validate the colocalization and distribution of these proteins. Results: Our findings revealed UBL3-positive inclusions in the cytoplasm and nuclei of neurons throughout the striatum of HD patients. We discovered that UBL3 colocalizes and interacts with mHTT and modulates its intracellular sorting. Conclusions: These results suggest that UBL3 may play a significant role in the interaction and sorting of mHTT, contributing to the understanding of its potential implications in the pathophysiology of Huntington’s disease.